Recruiting · registry status

People’s experiences when medication wears off

Researchers are learning how people experience periods when their Parkinson’s medicine wears off, and how they use the prescribed medicine Inbrija in everyday life.

Learning by observing or collecting information · Study reference: NCT07797790

Plain-language introduction written with AI from the registry; not independently checked by a clinician. Read the original details below ↓

Open the official registry record ↗

Who can join?

Age 18 years and over · Does not accept healthy volunteers

These are starting points, not the full rules. The research team can tell you whether the study is right for your situation.

Read all the rules for taking part

Sex eligibility reported by registry: all

Inclusion Criteria: * Adults aged 18 years or older. * Diagnosis of Parkinson's disease with a history of OFF episodes. * Able and willing to provide informed consent. For the Quantitative Component: • Physician decision to initiate Inbrija® for the treatment of OFF episodes in Parkinson's disease according to routine clinical practice prior to enrollment. For the Qualitative Component: * Current user of Inbrija® for OFF episodes in Parkinson's disease according to approved prescribing conditions. * At least 6 weeks of regular Inbrija® use (minimum 4 uses during the previous month). * Able to participate in a 60-minute interview using an internet-enabled device. Exclusion Criteria: For the Quantitative Component: * Previous use of Inbrija® before study enrollment. * Participation in an interventional Parkinson's disease clinical trial within 3 months prior to Inbrija® initiation. * Residence outside Austria, Germany, or Sweden. * Current use of an on-demand treatment for OFF episodes other than Inbrija®. For the Qualitative Component: * Participation in an interventional Parkinson's disease clinical trial within 3 months prior to enrollment. * Residence outside Austria or Germany. * Current use of an on-demand treatment for OFF episodes other than Inbrija®.

Full study name & original research details

Official study title

Real-world Patient Experiences With Inbrija® - Non-interventional Assessment of Inhaled Levodopa for the Management of OFF Episodes in Parkinson's Disease: a Mixed-methods Study

Short title used by the registry

Real-world Patient Experiences With Inbrija®

Original description

Parkinson's disease can cause OFF episodes, when medication effects wear off and symptoms return, affecting movement, daily activities, comfort, and wellbeing. This study aims to explore the experiences of people with Parkinson's disease who are prescribed Inbrija® as part of their usual care. Through a mixed-methods approach, the study will examine how OFF episodes affect patients, what influences their decision to use Inbrija®, and whether patient-reported outcomes related to symptoms, daily functioning, and quality of life change during the first 3 months of treatment. The study is planned to be conducted at approximately 7 sites in Austria, Germany, and Sweden and will enroll up to 120 participants receiving Inbrija® in routine clinical practice.

Further description from the registry

INHALE-PD is a multicenter, non-interventional observational study conducted in Austria, Germany, and Sweden. The study will enroll adults with Parkinson's disease who experience OFF episodes and have been prescribed Inbrija® as part of routine clinical care. The study aims to characterize patient experiences of OFF episodes and to assess patient-reported outcomes associated with Inbrija® use in routine clinical practice. Using qualitative interviews and patient-reported outcome assessments, the study will explore the impact of OFF episodes on patients' daily lives, factors influencing the use of Inbrija®, and changes in patient-reported outcomes during the observation period.

Conditions reported: Parkinson Disease (PD); Parkinson's Disease; Off Episodes of Parkinson Disease

Study type: Observational
Interventions: Levodopa inhalation powder
Phases: Not reported
Sponsor: Merz Therapeutics GmbH
Start date reported by registry: 2026-09 (estimated)

Registry updated: 2026-10-02 · Status last verified by the registry submitter: 2026-09

Registry records retrieved 2026-10-11 (UTC). Individual records may have older updates. Recruitment and eligibility must be confirmed with the study team.

Contact the research team

Public study contacts supplied to the registry. Ask whether recruitment is still open and what participation involves.

Public Disclosure Manager · +496915030 · clinicaltrials@merz.de

Study locations

Site status can differ from overall study status. “Status not reported” means local availability needs confirmation. Remote participation and travel arrangements must be checked with the team.

Neurologisches Therapiezentrum Gmundnerberg GmbH

Altmünster, Austria

Not yet recruiting

Medizinischen Universität Graz

Graz, Austria

Recruiting

The original descriptions and participation rules come from the registry. Participation is voluntary and does not guarantee benefit.